/**
 * Drug-Eluting Stents cluster — "Stent Platform and Polymer Technology"
 */

import type { ContentBlock, TocItem } from "../blog";

export const STENT_PLATFORM_TOC: TocItem[] = [
  { id: "platform-materials", title: "Metallic Platform Materials" },
  { id: "strut-design", title: "Strut Design and Deliverability" },
  { id: "polymer-role", title: "The Role of the Polymer Coating" },
  { id: "polymer-types", title: "Durable, Biodegradable and Polymer-Free Approaches" },
  { id: "drug-release", title: "Drug Release Kinetics" },
  { id: "selection", title: "Practical Implications for Device Selection" },
  { id: "faq", title: "Frequently Asked Questions" },
  { id: "conclusion", title: "Conclusion" },
];

export const STENT_PLATFORM_CONTENT: ContentBlock[] = [
  {
    type: "intro",
    paragraphs: [
      "Behind every drug-eluting stent implanted in the cath lab is an engineering system combining a metallic platform, a coating technology and a drug-release strategy. AbuFarha Medical supplies drug-eluting stents from established manufacturers and supports cath lab teams with the technical understanding needed to evaluate platform and coating options against local case mix.",
      "The metallic platform and the polymer coating are not incidental packaging around the drug; they are engineered together to determine how the device tracks through the vasculature, how it behaves once expanded, and how the vessel wall heals over months and years. Differences between device families are frequently differences in this underlying engineering rather than in the drug itself.",
      "This article explains platform materials and strut design, the function of the polymer coating, the main coating strategies in current use, and how these factors translate into practical considerations for device selection in a hospital setting.",
    ],
  },
  {
    type: "keyFacts",
    covers:
      "Metallic platform materials, strut geometry, polymer coating strategies, drug release kinetics and their practical implications for device selection",
    audience:
      "Interventional cardiologists, cath lab technical staff, biomedical engineers, procurement and clinical evaluation committees",
    readingTime: "12 min read",
    technology: "Drug-Eluting Stents",
  },
  {
    type: "h2",
    id: "platform-materials",
    text: "Metallic Platform Materials",
    number: 1,
    body: "The underlying alloy determines radial strength, flexibility and how thin the struts can be made.",
  },
  {
    type: "p",
    text: "Contemporary drug-eluting stent platforms are most commonly manufactured from cobalt-chromium or platinum-chromium alloys, chosen for their combination of radial strength and flexibility at reduced material thickness compared with older stainless steel platforms. A stronger alloy allows thinner struts for a given level of mechanical support, which in turn affects deliverability and the vessel's healing response.",
  },
  {
    type: "knowledgeBox",
    variant: "did-you-know",
    title: "Thinner struts generally support faster healing",
    text: "Reducing strut thickness, made possible by higher-strength alloys, is associated with more favourable vessel healing patterns and reduced disruption to blood flow at the strut surface compared with thicker designs.",
  },
  {
    type: "h2",
    id: "strut-design",
    text: "Strut Design and Deliverability",
    number: 2,
  },
  {
    type: "ul",
    items: [
      "Strut thickness affects both deliverability through tortuous vessels and the surface area available for drug and polymer coating.",
      "Cell geometry — the pattern of connections between struts — influences flexibility during delivery and radial support once deployed.",
      "Radiopacity markers on the platform allow the operator to visualise stent position and expansion under fluoroscopy.",
      "Foreshortening and recoil characteristics affect how precisely the operator can place the device relative to the target lesion.",
      "Platform conformability affects apposition to the vessel wall, particularly in curved or irregular anatomy.",
    ],
  },
  {
    type: "h2",
    id: "polymer-role",
    text: "The Role of the Polymer Coating",
    number: 3,
  },
  {
    type: "p",
    text: "The polymer coating serves as the drug reservoir and controls the rate at which the drug is released into the surrounding vessel wall. Beyond drug delivery, the biocompatibility of the polymer itself affects the local inflammatory response and the pace and completeness of vessel healing. Polymer choice has therefore been a central focus of device evolution across successive DES generations.",
  },
  {
    type: "table",
    headers: ["Polymer approach", "General characteristic", "Design intent"],
    rows: [
      ["Durable polymer", "Remains on the stent permanently after drug elution completes", "Long-established approach with extensive clinical use history"],
      ["Biodegradable polymer", "Degrades over time after the drug has been released", "Intended to leave a bare metal-like surface once its function is complete"],
      ["Polymer-free", "Drug bound directly to the platform surface or a textured coating", "Removes the polymer as a long-term implanted material altogether"],
    ],
  },
  {
    type: "tableInsight",
    expertCommentary:
      "Each polymer strategy represents a different trade-off between long-term biocompatibility and the manufacturing maturity and clinical familiarity of durable-polymer platforms.",
    clinicalInterpretation:
      "No single polymer strategy is universally superior across all patients; the treating cardiologist selects based on lesion, patient factors and institutional experience.",
    hospitalRecommendation:
      "Cath labs should maintain familiarity with the specific polymer characteristics of the device families they stock, since handling, deployment technique and expected healing timelines can differ.",
  },
  {
    type: "h2",
    id: "polymer-types",
    text: "Durable, Biodegradable and Polymer-Free Approaches",
    number: 4,
  },
  {
    type: "ul",
    items: [
      "Durable-polymer platforms have the longest clinical track record and remain widely used across contemporary practice.",
      "Biodegradable-polymer platforms aim to combine early anti-proliferative benefit with a longer-term profile closer to a bare metal stent once the polymer has resorbed.",
      "Polymer-free platforms eliminate polymer-related considerations entirely, relying on surface texturing or direct drug binding for elution.",
      "Selection among these approaches is a clinical decision made by the treating interventional cardiologist based on patient and lesion characteristics, not a purely procurement-driven choice.",
    ],
  },
  {
    type: "knowledgeBox",
    variant: "engineer-note",
    title: "Coating strategy affects storage, not just biology",
    text: "Some coating chemistries carry specific storage temperature or handling requirements to preserve coating integrity before implantation. Cath lab inventory teams should follow manufacturer storage instructions precisely rather than applying a single standard to all stocked devices.",
  },
  {
    type: "h2",
    id: "drug-release",
    text: "Drug Release Kinetics",
    number: 5,
  },
  {
    type: "p",
    text: "The rate at which the drug elutes from the polymer into the vessel wall is engineered to match the timeline over which the anti-proliferative effect is needed, generally concentrated in the weeks following implantation while the vessel undergoes its initial healing response. Release kinetics are a function of polymer composition, coating thickness and drug loading, and are established by the manufacturer through their device development and testing programme rather than adjustable at the point of use.",
  },
  {
    type: "h2",
    id: "selection",
    text: "Practical Implications for Device Selection",
    number: 6,
  },
  {
    type: "ul",
    items: [
      "Match platform flexibility and profile to the anatomical complexity typically encountered in the local case mix.",
      "Consider strut thickness where bifurcation lesions or smaller vessels are common, since deliverability and side-branch access can be affected.",
      "Maintain operator familiarity with a rationalised set of platforms rather than frequent switching, since deployment technique varies subtly between devices.",
      "Track manufacturer updates to platform or coating generation, since successive iterations can change handling and expected performance.",
      "Coordinate device selection with the antiplatelet therapy strategy planned for the patient, since some clinical scenarios influence platform choice.",
    ],
  },
  {
    type: "p",
    text: "AbuFarha Medical supplies drug-eluting stents spanning established platform and polymer technologies, and works with cath lab teams to align device family selection with case mix, storage requirements and procedural technique through ongoing biomedical engineering and clinical liaison support.",
  },
  {
    type: "faq",
    items: [
      {
        q: "Why do drug-eluting stents use cobalt-chromium or platinum-chromium alloys rather than stainless steel?",
        a: "These alloys offer greater radial strength at reduced thickness, allowing thinner struts that support easier delivery and more favourable vessel healing compared with older stainless steel platforms.",
      },
      {
        q: "Is a biodegradable polymer better than a durable polymer?",
        a: "Neither approach is universally superior; each has a different long-term profile and trade-off, and the treating interventional cardiologist selects based on the individual patient and lesion.",
      },
      {
        q: "Does strut thickness matter clinically?",
        a: "Yes. Thinner struts are generally associated with easier deliverability and more favourable vessel wall healing, though the platform's overall design and clinical context also matter.",
      },
      {
        q: "Can drug release rate be adjusted after manufacture?",
        a: "No. Release kinetics are fixed by the manufacturer's coating composition, thickness and drug loading during device development, and are not adjustable at the point of implantation.",
      },
      {
        q: "Does polymer choice affect how a stent should be stored?",
        a: "It can. Some coating chemistries have specific temperature or handling requirements, and cath lab inventory teams should follow the manufacturer's storage instructions for each device family precisely.",
      },
    ],
  },
  {
    type: "h2",
    id: "conclusion",
    text: "Conclusion",
    number: 7,
  },
  {
    type: "p",
    text: "Platform alloy, strut design and polymer coating strategy together determine how a drug-eluting stent is delivered, deployed and how the treated vessel heals over time. Understanding these engineering fundamentals allows clinical and procurement teams to evaluate device families on their genuine technical merits rather than on branding alone.",
  },
  {
    type: "editorialBoard",
    reviewers: [
      { role: "Clinical review", name: "AbuFarha Clinical Editorial Board", credential: "Interventional cardiology device practice" },
      { role: "Engineering review", name: "AbuFarha Biomedical Engineering", credential: "Cath lab consumables and device technical support" },
    ],
    lastReviewed: "July 31, 2026",
    nextReview: "July 31, 2027",
    version: "1.0",
    evidenceLevel: "Manufacturer technical documentation and established interventional cardiology engineering principles",
    disclaimer:
      "Educational guidance on stent platform and polymer technology. It does not replace manufacturer instructions for use or clinical judgement.",
  },
  {
    type: "references",
    items: [
      { label: "Manufacturer technical documentation for drug-eluting coronary stent platforms and coatings." },
      { label: "Institutional interventional cardiology device evaluation and formulary records." },
      { label: "Established engineering principles applicable to intravascular metallic implants." },
    ],
  },
];
